Background
Investors brought a putative class action against Apellis Pharmaceuticals, Inc. and its CEO, Dr. Cedric Francois, under Sections 10(b) and 20(a) of the Securities Exchange Act and SEC Rule 10b-5. They challenged statements that no cases of retinal vasculitis had been observed among participants in the OAKS and DERBY Phase III trials of pegcetacoplan, later approved as SYFOVRE to treat geographic atrophy.
The investors did not allege that the statements were factually false. Instead, they claimed the statements were misleading half-truths because Apellis did not disclose that the trials were allegedly not designed to detect retinal vasculitis. The district court dismissed the complaint, concluding both that the challenged omissions did not make the statements materially misleading and that the complaint failed to plead scienter.
The Court’s Holding
The First Circuit affirmed, holding that the complaint did not plausibly allege an actionable material misrepresentation or omission. The publicly available, FDA-approved trial protocols fully disclosed when fluorescein angiograms—the commonly accepted test for retinal vasculitis—would be administered. The protocols required angiograms at the beginning, midpoint, and end of the trials, as well as after participants withdrew, and allowed clinicians to order additional testing when symptoms warranted it.
Because investors had access to accurate information about the testing procedures, the court concluded that Apellis did not withhold critical qualifying information when reporting that no retinal vasculitis had been observed. The protocols were followed, the testing could detect retinal vasculitis, and no participant was shown to have developed the condition. The court therefore affirmed on materiality grounds without deciding whether the plaintiffs adequately pleaded scienter.
Key Takeaways
- A literally true statement may support securities-fraud liability as a misleading half-truth only when it omits critical qualifying information.
- Accurate statements about clinical-trial results were not misleading where the trial protocols publicly disclosed the relevant testing procedures and no contrary result was concealed.
- The First Circuit affirmed dismissal without reaching the district court’s independent ruling that the complaint failed to plead scienter.
Why It Matters
The decision limits half-truth liability where a pharmaceutical company accurately reports clinical-trial findings and publicly discloses the protocols underlying those findings. A disagreement over whether the protocols should have required more frequent or differently timed testing does not, without a concealed material fact or factual contradiction, make accurate trial-result statements actionable.
The court left open the possibility that technically dense public disclosures might not prevent liability in another case if reasonable investors could still be misled by simpler public statements. On the allegations here, however, the disclosed protocols and accurate results defeated the investors’ theory.